NCT00100698View on ClinicalTrials.gov

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

April 30, 2009

Conditions
AIDSHIV Infections
Interventions
DRUG

recombinant human growth hormone

growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months

DRUG

placebo

placebo subcutaneously once a day, 18 months

Trial Locations (1)

02114

MGH, Boston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00100698 - Physiologic Growth Hormone Effects in HIV Lipodystrophy | Biotech Hunter | Biotech Hunter